-
Pfizer and BioNTech Receive Positive CHMP Opinion for Comirnaty Vaccine
•
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on the Omicron XBB.1.5-adapted monovalent version of the SARS-CoV-2 vaccine Comirnaty, developed in partnership by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX). The vaccine is intended for use in children…
-
Dizal Pharmaceutical’s Golidocitinib Earns Priority Review for r/r PTCL Treatment in China
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its drug golidocitinib has been included in the priority review list for the treatment of recurrent or refractory peripheral T-cell lymphoma (r/r PTCL) in patients who have received at least one standard treatment. The priority status indicates the drug’s filing…
-
Ronovo Surgical Secures Pre-Series B+ Funding to Advance Modular Surgical Robots
•
Shanghai-based minimally invasive surgical robot developer, Ronovo Surgical, has reportedly raised close to RMB 200 million (USD 27.5 million) in a pre-Series B+ financing round. The round was led by NRL Capital, with contributions from Kington Capital, Lilly Asia Ventures, Vivo Capital, Matrix Partners, GGV Capital, and LongRiver Investments. The…
-
AIM Vaccine Co., Ltd Launches Phase III Trial for 23-Valent Pneumococcal Vaccine
•
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced the commencement of a Phase III clinical study for its 23-valent pneumococcal polysaccharide vaccine. The study is designed as a randomized, blind, similar vaccine-controlled trial, expected to enroll 1920 healthy subjects aged two years and older. Targeting Invasive Pneumococcal DiseasesThe 23-valent…
-
Kangpu Biopharmaceuticals Secures Series B Funding to Advance Molecular Glue Therapies
•
Shanghai-based Kangpu Biopharmaceuticals, Ltd has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series B financing round. The round was led by V-Capital, with additional investments from Northern Light Venture Capital, Lapam Capital, Yijing Capital, Realharmony Capital, and Yinxinggu Capital. The proceeds from this funding will…
-
Epigenic Therapeutics Secures $32 Million in Series A Funding for Gene Modulation Therapy
•
Epigenic Therapeutics, a Shanghai-based biotech company specializing in gene modulation therapy through epigenome regulation, has successfully raised USD 32 million in a Series A financing round. The round was co-led by Qiming Venture Partners and OrbiMed, with participation from existing investor Morningside Venture Capital. The funds will be utilized to…
-
Biocytogen Pharmaceuticals’ Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd’s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced a technology transfer agreement with US firm Syncromune. This agreement builds upon an earlier licensing deal made in 2022, which resulted in Eucure transferring rights related to the drug candidate YH002 and other clinical stage…
-
CSPC Pharmaceutical’s Biosimilar Ozempic Equivalent Gets NMPA Clinical Trial Approval
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its biosimilar version of Novo Nordisk’s (NYSE: NVO) GLP-1 analog Ozempic (semaglutide) has obtained clinical trial approval from the National Medical Products Administration (NMPA). The upcoming trial will assess the use of CSPC’s biosimilar in maintaining blood sugar control in…
